Navigation Links
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDF's 20th World Diabetes Congress
Date:10/21/2009

>

Otelixizumab is a targeted T-cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T-cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T-cell immunomodulator partnered with GlaxoSmithKline in Phase 3 development for the treatment of type 1 diabetes; a Phase 1 candidate, MTRX1011A, an anti-CD4 antibody that is being developed in collaboration with Genentech, Inc. for the treatment of autoimmune indications; and two pre-clinical candidates, TRX518 and TRX385, that enhance immune responses and are being evaluated for potential benefit in the treatment of cancer, chronic viral diseases, and as vaccine adjuvants. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.

SOURCE Tolerx, Inc.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
3. Laureate Announces Manufacturing Agreement with Tolerx
4. Tolerx Named as One of the Fierce 15 Biotech Companies of 2008
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
9. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
10. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
11. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have ... drug development approval process. Thus, innovator companies must understand what will be needed ... Chicago-based CMO, has been hosting multiple educational panels and seminars for experts to ...
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Global & USA BioSimilar Market Analysis ... The highly awaited US Biosimilar market will be initiated ... biologic, Zarxio. How will the global market react? Will ... that biosimilars could save the US economy up to ...
(Date:8/28/2015)... Texas (PRWEB) , ... August 28, 2015 , ... ... Riordan, PhD and orthopedic surgeon, Wade McKenna, DO, announced today that the use ... Dallas, Texas, resulted in complete healing of an otherwise non-healing surgical knee wound. ...
(Date:8/27/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), announced today that dosing ... BHV-0223, a glutamate modulating agent. Biohaven filed an ... obtained clearance from the U.S. Food and Drug ... holds 54% equity interest in Biohaven, a private ...
Breaking Biology Technology:Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 2Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 3Dallas-Fort Worth Stem Cell Researchers Use Amniotic Tissue To Successfully Treat Non-Healing Surgical Wound 4Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... VIENNA, Austria, March 12 f-star, an antibody,engineering ... its unique Modular Antibody Technology, announced today that ... in addition to its,headquarters in Vienna, Austria. The ... home to a number of biotech companies and ...
... March 12 iCAD, Inc. (Nasdaq:,ICAD), an industry-leading ... detection of cancer, today announced that John,DeLucia has ... Assurance and,Regulatory Affairs, reporting to iCAD President and ... years of medical device, in-vitro diagnostics,and biomedical research ...
... REDWOOD CITY, Calif., March 12 Genomic,Health, Inc. ... Scott, Ph.D.,Genomic Health,s Chairman and Chief Executive Officer, ... Healthcare Conference in Miami, FL,on March 19, 2008 ... the live and subsequently archived webcast of the,presentation, ...
Cached Biology Technology:Antibody Engineering Company f-Star Opens Second Research Site in Cambridge, UK 2iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs 2iCAD Appoints John DeLucia as Vice President of Quality Assurance and Regulatory Affairs 3Genomic Health to Present at Lehman Brothers Global Healthcare Conference 2
(Date:8/5/2015)... Transparency Market Research has released ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... is forecast to reach US$ 2,671.8 Mn by 2022. ... systems by civil and government agencies. This is majorly ... activities across the globe that would elevate the demand ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... AND RFID FOR STOCK ... INVENTORY AND STORE FRONT SOLUTION, SAN JOSE, Calif., Dec. 18 ... security,solutions provider announced today the launch of a new product tailor-made,for ... new,product,s purpose is to provide the retail industry a total solution ...
... than a millionth of a millimeter in diameter ... to drive carbon dioxide uptake, fueling the marine ... A new study published in this weeks PLoS ... a team of scientists from MountAllison University, Sackville, ...
... (Dec. 18, 2007)Researchers at The University of Texas Medical ... regulating glucose metabolism and spina bifida. The decade-long study ... and their children with that birth defect. UT ... that take part in glucose metabolism to look for ...
Cached Biology News:Titanium Group Announces Launch of New Identification Solution Targeting High Growth Retail Sector 2Titanium Group Announces Launch of New Identification Solution Targeting High Growth Retail Sector 3Variable light illuminates the distribution of picophytoplankton 2UT-Houston's Northrup and colleagues uncover genetic link to spina bifida 2
... Time-resolved microscopy is the ultimate tool ... subcellular structures. Its applications previously have been ... because microscope optics do not transmit in ... leader in fluorescence spectroscopy, introduces a filter-based ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ID ...
... crystallography involves using many of the automation ... liquid handling requirements are similar to those ... plates have 24 or 48 wells with ... higher throughput, the number of wells has ...
... assay can detect H2O2 or peroxidase activity ... oxidizes ADHP in a 1:1 stoichiometry to ... 530-571 nm, emission at 590-600 nm). This ... one-step, homogeneous, no wash assay system. ADHP ...
Biology Products: